Phase 1 bioequivalence study of dapagliflozin/sitagliptin FDC vs loose combination of single components

Trial Identifier: D1683C00014
Sponsor: AstraZeneca
NCTID:: NCT05266404
Start Date: March 2022
Primary Completion Date: May 2022
Study Completion Date: May 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
German Translation

Trial Locations

Country Location
DE Berlin, DE, 14050